 |
4-(6-(4-(piperazin-1-yl)phenyl_pyrazolo[1,5-a]pyrimidin-3-yl)quinoline hydrochloride |
|---|---|
| Trade Name | |
| Orphan Indication | Fibrodysplasia ossificans progressiva |
| USA Market Approval | USA |
| USA Designation Date | 2013-04-15 00:00:00 |
| Sponsor | La Jolla Pharmaceutical Company, Inc.;10182 Telesis Court, Suite 600;San Diego, California, 92121 |
